RxDoctor Payments Data

Ross Pirkle, MD

Internal Medicine · Walnut Creek, CANPI 1184656688

Payments from drug & device makers

$12,419in general payments, 2019–2025

Across 485 payments — averaging $25.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$1K
  • Amgen$1K
  • Boehringer Ingelheim$933
  • GSK$928
  • AstraZeneca$839
  • plus $5K from 46 others

What the payments were for

  • Food & beverage$12,389100%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,419 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$290,329
Medicare patients
314
Services billed
9,420

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin73$91,067
EliquisApixaban46$56,270
MounjaroTirzepatide50$54,003
OzempicSemaglutide29$30,154
MyrbetriqMirabegron27$20,708
XareltoRivaroxaban11$15,631
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$14,156
FarxigaDapagliflozin Propanediol11$10,518
OxycontinOxycodone Hcl12$5,561
Buprenorphine28$5,348
Rosuvastatin Calcium277$5,226
Mesalamine ErMesalamine12$4,556
Metoprolol Succinate125$2,657
Atorvastatin Calcium233$2,647
Levothyroxine Sodium158$2,535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$933$91,06773 claims
PfizerEliquis, Paxlovid$1,481$57,70073 claims
Lilly USA, LLCMounjaro$777$54,00350 claims
Novo NordiskOzempic$584$30,15429 claims
Astellas Pharma US IncMyrbetriq$137$20,70827 claims
Johnson & JohnsonXarelto$816$15,63111 claims
GSKTrelegy Ellipta$928$14,15622 claims
AstraZenecaFarxiga$839$10,51811 claims
AbbVieSynthroid$2,136$2,06125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Walnut Creek

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →